Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 79 Publications

17 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7kcJY1KGR? M4H3SGlEPTB;NT63NFUhKM7:TTC= NVftV4pXOTh3NUm2NVM>
KP6.3 M1;xfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\NUXU1KGR? MmGxTWM2OD1zMD60Nlgh|ryPIB?= NWfJfJBOOTh3NUm2NVM>
KP7.7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;4OEBl M{nobmlEPTB;NUegcm0h MmHaNVg2PTl4MUO=
KB2P3.4 M{DTXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUe0JIQ> NGrUblhKSzVyPUGyOEBOKA>? M4HK[lE5PTV7NkGz
KB2P1.21 NXOzN2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonXOEBl MUfJR|UxRTh7MEegcm0h MmLjNVg2PTl4MUO=
U373-MG M3jEPGN6fG:2b4jpZ{BCe3OjeR?= Moj4NUDPxE1i MlPzNlQhcA>? NH[3WJdKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MkLaNVg6PTR5MUK=
T98G MXnDfZRwfG:6aXOgRZN{[Xl? NXTuPZZ7OSEQvF2g M4mzcFI1KGh? MYPJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 MmrvNVg6PTR5MUK=
U87-MG MYPDfZRwfG:6aXOgRZN{[Xl? M3;XTFEh|ryPIB?= MWmyOEBp MX\JcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NWXSSo5bOTh7NUS3NVI>
UVW NVrNc3lOS3m2b4TvfIlkKEG|c3H5 NGDISI02ODBibl2= MW[yOEBp MX7JcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 M{fLOlE5QTV2N{Gy
HeLa MnG4SpVv[3Srb36gRZN{[Xl? NYO1VoF2PTByIH7N NVizfIYzPCCq MV7DZZV{\XNiYTDtc4Rme3RiZHXsZZkhcW5icnXqc4lvcW6pIH;mJJJi\GmjdHnvck1qdmS3Y3XkJGRPSSCkcnXhb5M> NYjVPGVNOTh7NUS3NVI>
HeLa NF7ufXVHfW6ldHnvckBCe3OjeR?= MlHxNUDPxE1i Mlv5NlQhcA>? NHXTRVNGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= Mo\0NVg6PTR5MUK=
T98G Mn:0SpVv[3Srb36gRZN{[Xl? NHrqPG4yKM7:TTC= NIDxfGQzPCCq M4DNdGVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 NYrxRmdtOTh7NUS3NVI>
L3 Mk\oR5l1d3SxeHnjJGF{e2G7 NV\uZ45nPSEQvF2g NVvXXIw3QTZiaB?= MV;EUXNQ MoHJV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NWjWTWtLOjBzMkS0OVk>
Granta-519 MnrVR5l1d3SxeHnjJGF{e2G7 M123XlUh|ryPIB?= MXq5OkBp NFO1enVFVVOR NYXPfoNmW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= M1zI[lIxOTJ2NEW5
BT M{PKW2N6fG:2b4jpZ{BCe3OjeR?= NWjiV|I{PSEQvF2g MUe5OkBp M4fM[GROW09? M2HDbXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? Ml3WNlAyOjR2NUm=
UPN2 NXPBUHQ3S3m2b4TvfIlkKEG|c3H5 NFXnUZo2KM7:TTC= M3rVXVk3KGh? NVroNI9vTE2VTx?= NH3JZ2FUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NE\v[4ozODF{NES1PS=>
HBL-2 MWLDfZRwfG:6aXOgRZN{[Xl? MkfyOUDPxE1i M4TMXVk3KGh? NWfy[ZdNTE2VTx?= NFTPNnVUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M{DBXFIxOTJ2NEW5
JVM-2 MmPsR5l1d3SxeHnjJGF{e2G7 M1vobFUh|ryPIB?= M{DvPFk3KGh? NHXsR4pFVVOR NYnnT3ZOW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NUf6PHNkOjBzMkS0OVk>
Z138 NY\5UYV{S3m2b4TvfIlkKEG|c3H5 NGTsclY2KM7:TTC= MmrhPVYhcA>? MVHEUXNQ NHXEe5ZUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MUCyNFEzPDR3OR?=
RWPE NUPWO3VrUW64YYPpeoUhSXO|YYm= MWKyOUDPxE1? NWqyengxPDhiaB?= MXjEUXNQ M2fObXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> MnnwNlE2PzV6NkW=
VCaP MV7JcpZie2m4ZTDBd5NigQ>? M3rKU|I2KM7:TR?= MXu0PEBp M4rROmROW09? MoLSV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=> NVSwdlJZOjF3N{W4OlU>
Mouse H2AX−/− ES Cells MlTMR5l1d3SxeHnjJGF{e2G7 M4PvclIvPSEQvF2= NFS2SlMzOCCq NVzESHdHW2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NXfJW21rOjN|NUW0PFk>
Mouse ATM−/− ES Cells NYj6VYtSS3m2b4TvfIlkKEG|c3H5 NUL3[YplOi53IN88US=> NX:2THNkOjBiaB?= MVLTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= MUmyN|M2PTR6OR?=
H1650 NXSwSG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzLNlAh|ryP NGX2e|YyPDRiaB?= Mlf0TWM2OD1zNT60O{DPxE1? NYHvfoh{OjN{M{m4NFk>
H1650PTEN+ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXJNlAh|ryP MXyxOFQhcA>? NXXkPWxCUUN3ME21NE45OyEQvF2= MmHNNlMzOzl6MEm=
PC-9 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjJZ|ZJOjBizszN MnG5NVQ1KGh? M2nJOGlEPTB;NT64PEDPxE1? NG\RN2szOzJ|OUiwPS=>
PC-9PTEN− MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvO|IxKM7:TR?= MkDaNVQ1KGh? MVXJR|UxRTZwNUKg{txO NE\ZNmwzOzJ|OUiwPS=>
MDA-MB-231 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETSdI02KGSjeR?= NFvGRpVKSzVyPU[uPUDPxE1? NEi3OW4zOzd4MES5Oi=>
MDA-MB-468 M2i4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DFR|Uh\GG7 NWLiU2pvUUN3ME21MlAh|ryP NH\3R3kzOzd4MES5Oi=>
BT20 M1;jWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rwOVUh\GG7 MVTJR|UxRTdwNzFOwG0> NYC1cVg{OjN5NkC0PVY>
HCC1143 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;mOUBl[Xl? M4e0SmlEPTB;MUGuNUDPxE1? NXvZWHBZOjN5NkC0PVY>
HCC1937 M2C3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[1JIRigQ>? NWTPPGlwUUN3ME2xNk43KM7:TR?= NXjXbJJJOjN5NkC0PVY>
Hs578t M1Hjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TZOVUh\GG7 NUXlSlROUUN3ME21MlYh|ryP NWO0eoppOjN5NkC0PVY>
Hs578t(si) M4\wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:5OUBl[Xl? NITDZpBKSzVyPUeuOUDPxE1? NG\SPIozOzd4MES5Oi=>
BT474 M2\IdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[1JIRigQ>? NWjsUYJ1UUN3ME2xPU45KM7:TR?= NVG5ZZNtOjN5NkC0PVY>
JIMT1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnUPVE2KGSjeR?= MXTJR|UxRTdwNzFOwG0> NF;NcIYzOzd4MES5Oi=>
SKBR3 NFnoW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:1JIRigQ>? M1rpdmlEPTB;MUGuNUDPxE1? MnPLNlM4PjB2OU[=
SUM159 NUPkUlc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXpPYVWPSCmYYm= NHnUSmtKSzVyPUSuNkDPxE1? MUmyN|c3ODR7Nh?=
CAMA1 M{OzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHBbYQ2KGSjeR?= MXrJR|UxRTF3Lkig{txO MkXRNlM4PjB2OU[=
MCF7 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[wVFJZPSCmYYm= MWHJR|UxRTVwODFOwG0> MkfpNlM4PjB2OU[=
T47D NUTJVFROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Hzc|Uh\GG7 NXzKfndsUUN3ME25MlYh|ryP NGTjXWYzOzd4MES5Oi=>
HCT116 NYqyPJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PwOVExOCEQvF2= NYnveVBEPDhiaB?= M2TCS2ROW09? Mn\NTWM2OD1{LkWg{txOKA>? M2nQVVI1PTd5OUSx
SW1116 M3\lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLmPGMyODBizszN MnG5OFghcA>? M1\heWROW09? M3O3TGlEPTB;MUCwJO69VQ>? NXnROFA3OjR3N{e5OFE>
HT29 M3jtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzSVcyODBizszN MVu0PEBp M3zEd2ROW09? NIXDPZpKSzVyPUG0Mlch|ryP M3XWU|I1PTd5OUSx
LoVo M4nGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC3NVAxKM7:TR?= MXi0PEBp NFG4dFVFVVOR NIjXTYRKSzVyPUGzMlQh|ryP MlXJNlQ2Pzd7NEG=
HCT-15 NV:3UmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLFZ5VsOTByIN88US=> NWrQSnFxPDhiaB?= NUnYcIlLTE2VTx?= M4GxeWlEPTB;MUCg{txO NULU[5NqOjR3N{e5OFE>
SW48 NHX2elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmxRVlHOTByIN88US=> NIjWW|k1QCCq MY\EUXNQ NEfKU2lKSzVyPUmuOUDPxE1? M4fUXVI1PTd5OUSx
C-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD5TlFYOTByIN88US=> NFfUVJo1QCCq Mn[2SG1UVw>? MVnJR|UxRTdwNjFOwG0> MmTlNlQ2Pzd7NEG=
RKO MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPWfZBTOTByIN88US=> MWO0PEBp NUT4R4RZTE2VTx?= MXjJR|UxRTVwOTFOwG0> NXna[WFnOjR3N{e5OFE>
HCT116 NHi1Sm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLhU25NOTByIN88US=> MUC0PEBp MUfEUXNQ NYKxdWRZWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= M3q5b|I1PTd5OUSx
SW1116 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;SOVExOCEQvF2= NVfIbHlGPDhiaB?= NWjINnJsTE2VTx?= NIHvb21Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NIexcXEzPDV5N{m0NS=>
HT29 NUD5cod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\QNVAxKM7:TR?= NULMSZNNPDhiaB?= NHz6[GNFVVOR MkKxVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NGX0UoUzPDV5N{m0NS=>
LoVo MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDZfmd5OTByIN88US=> M1zWcVQ5KGh? NHe0SmxFVVOR NIrHVVZRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli M3nsXVI1PTd5OUSx
SW48 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvUbY8yODBizszN NFzaVZI1QCCq MW\EUXNQ M4OyWHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MlXSNlQ2Pzd7NEG=
C-1 NHX5doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLoNVAxKM7:TR?= MkLIOFghcA>? NXu4SnZiTE2VTx?= NVzmbphxWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= MnX3NlQ2Pzd7NEG=
RKO NWjvdZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNFAh|ryP M2m4clQ5KGh? MlPMSG1UVw>? M{DIbXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MXqyOFU4Pzl2MR?=
HCT116 M3zvXWZ2dmO2aX;uJGF{e2G7 MorGNVAhdk1? Mon5NVIhcA>? NUjWWGZXTE2VTx?= NWPmWphrUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 NVz1clJTOjR3N{e5OFE>
HT29 MlnsSpVv[3Srb36gRZN{[Xl? MUWxNEBvVQ>? MVmxNkBp Mln5SG1UVw>? Mn33TY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6 NEm0c4QzPDV5N{m0NS=>
TE-6 M{fEXmZ2dmO2aX;uJGF{e2G7 NFWxfVg2KM7:TTC= MlntNVIhcA>? NXnGU3RPTE2VTx?= NYix[5N6UW6mdXPld{BIOi:PIHHydoV{fA>? M{K0dFI1OjF7MU[0
TE-6 M4DtWGZ2dmO2aX;uJGF{e2G7 MUe1JO69VSB? MkLVNlQhcA>? NV3USZhpTE2VTx?= MmHzTY5kemWjc3XzJIlvKGSxdXLs[UB{fHKjbnSgZpJm[Wu|IDjEV2J{MQ>? MV:yOFIyQTF4NB?=
Hep3B Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX1NWs1OCEQvF2g NFvzbWQ4OiCq M3:2eGROW09? NFf5cHNUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? NWG0b3ZlOjVyN{K3OVI>
Huh7 M{LU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLJOFAh|ryPIB?= NHPZO3U4OiCq MWDEUXNQ Mnu5V5lv\XKpaYP0bYNidGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJJdqfGhiRFjNSXE> MXeyOVA4Ojd3Mh?=
Hep3B MnLvSpVv[3Srb36gRZN{[Xl? MkX0OFAh|ryPIB?= MVuyOEBp MkSxSG1UVw>? NXfJWJlbUW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR NYP5TllKOjVyN{K3OVI>
Huh7 NYiwbmJ5TnWwY4Tpc44hSXO|YYm= MV[0NEDPxE1i MnLtNlQhcA>? MUHEUXNQ NEHaZldKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= MWSyOVA4Ojd3Mh?=
Hep3B MnPhSpVv[3Srb36gRZN{[Xl? M4TQc|QxKM7:TTC= NEm3b5czPCCq NES5[GlFVVOR Mmm0TY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT MnzqNlUxPzJ5NUK=
Huh7 NXHMUIYyTnWwY4Tpc44hSXO|YYm= M3\RS|QxKM7:TTC= NXT3eVFjOjRiaB?= NVPBdoU1TE2VTx?= Mo\ITY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT NXHub2QyOjVyN{K3OVI>
SGC-7901 M4DIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj5T5Q{OMLizszN MkPvOFghcA>? MXvEUXNQ MXTCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi= Mm\iNlU4PjdyN{[=
COLO-800 NHfrZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml33TWM2OD1yLkS0NVY1KM7:TR?= NGizdXhUSU6JRWK=
EoL-1- NVvaUoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwNU[0OFYh|ryP M{Dx[nNCVkeHUh?=
NCI-H209 NFHVWmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwOUG1OVYh|ryP Mmj4V2FPT0WU
ES1 M165[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv5V3dKSzVyPUGuNVE1ODhizszN MkjJV2FPT0WU
NKM-1 M4PtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMkWzOFch|ryP NWrSbFVmW0GQR1XS
NTERA-S-cl-D1 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPEZmFrUUN3ME2xMlM{OzRzIN88US=> MWHTRW5ITVJ?
MHH-ES-1 NYHFOlNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPu[|BsUUN3ME2xMlYzODZ5IN88US=> NVzSOnJMW0GQR1XS
ES8 NUHDeVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTFwN{K0NVQh|ryP MV\TRW5ITVJ?
NCI-H720 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[zfWlEPTB;Mj6yNFY6QSEQvF2= NEfvOHJUSU6JRWK=
EW-3 NU\0XWl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPkTWM2OD1{LkK3OVM1KM7:TR?= M4G4ZnNCVkeHUh?=
D-566MG MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm1TWM2OD1{LkS0OVY5KM7:TR?= MWHTRW5ITVJ?
697 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfYZo9HUUN3ME2yMlg1OTd|IN88US=> NWjtdHQyW0GQR1XS
ES5 M4rwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwOEixPFkh|ryP NF:1[FZUSU6JRWK=
COLO-684 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C3OWlEPTB;Mz61NVY6PiEQvF2= MUfTRW5ITVJ?
ML-2 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXh[FBKSzVyPUOuOlAxPThizszN NWS3S3NJW0GQR1XS
MC-IXC NIfGVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HON2lEPTB;Mz62N|M6OyEQvF2= NIPRNJRUSU6JRWK=
DB M{Dob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17DbGlEPTB;Mz62OVQ1QCEQvF2= MkewV2FPT0WU
HCC2218 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL2VJRKSzVyPUOuO|MyODNizszN M2X0cXNCVkeHUh?=
NCI-H510A MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwOEK3NlQh|ryP M2[4dHNCVkeHUh?=
NCI-H526 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm4UFFKSzVyPUOuPFY6PThizszN MX\TRW5ITVJ?
MV-4-11 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3hTWM2OD12LkGzN|M1KM7:TR?= MljuV2FPT0WU
PA-1 NHiwcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTUZodKSzVyPUSuNlUzQSEQvF2= M2TyVXNCVkeHUh?=
EW-22 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDxcFRKSzVyPUSuN|U5PiEQvF2= Mn\DV2FPT0WU
KASUMI-1 NXq1epJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXDflVKSzVyPUSuOFAyODlizszN M{LLOXNCVkeHUh?=
LU-139 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD1UYpXUUN3ME20Mlc2QDJ7IN88US=> NYXt[YxLW0GQR1XS
SBC-1 NXrVdJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfZcYtoUUN3ME20MlgxQTB6IN88US=> MWPTRW5ITVJ?
H4 M3SwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLqS5NKSzVyPUSuPFk1PDNizszN NV3GcWFQW0GQR1XS
EW-11 NICzdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfJXFBrUUN3ME21MlA5ODd{IN88US=> NV\LS41RW0GQR1XS
NBsusSR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1dmxKSzVyPUWuNVIxPTVizszN NXTlWoEyW0GQR1XS
RPMI-8226 NH3rWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7jVo1sUUN3ME21MlE2OjR2IN88US=> MY\TRW5ITVJ?
DEL NFr6UGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPTd2hKSzVyPUWuNlAxODZizszN Mmj6V2FPT0WU
ES4 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjaNZF1UUN3ME21MlUyOzh7IN88US=> MkjxV2FPT0WU
GCT MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfJbYNpUUN3ME21MlU3QDV4IN88US=> NHKzfm9USU6JRWK=
NCI-H1048 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnjR|NKSzVyPUWuPVczPzNizszN M33IR3NCVkeHUh?=
NCI-SNU-1 M4PP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rzNmlEPTB;Nj6wNlIh|ryP NX;u[o03W0GQR1XS
ES7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:4eopyUUN3ME22MlA{PTd5IN88US=> NYmwO2lQW0GQR1XS
SW982 NHH2c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rndGlEPTB;Nj6wPVE{PyEQvF2= MWHTRW5ITVJ?
L-363 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TvUmlEPTB;Nj6zN|k4PCEQvF2= MW\TRW5ITVJ?
HT-1080 NELJOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZwNEm2PFMh|ryP Mnj5V2FPT0WU
HAL-01 NUfqPFFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf6e5lnUUN3ME22MlUyODlizszN MnzJV2FPT0WU
NB14 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwNkSwN|kh|ryP MlXGV2FPT0WU
EW-13 NFL5eXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17mdmlEPTB;Nj63O|QzPCEQvF2= NUWxcIdCW0GQR1XS
NY MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PLR2lEPTB;Nj65OFYxPSEQvF2= MUXTRW5ITVJ?
NCI-SNU-5 NYjxNnd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPOdFVKSzVyPUeuNVA1OzNizszN MX;TRW5ITVJ?
MS-1 M3iyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHNTWM2OD15LkG3OFk1KM7:TR?= MonyV2FPT0WU
EW-16 M3XTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;kS2lEPTB;Nz6zNVg3OSEQvF2= M1uxTHNCVkeHUh?=
LU-65 NUKze2hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwNEi0NVch|ryP M2rVXXNCVkeHUh?=
HGC-27 NUPWT4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHYb|lKSzVyPUeuO|IyPzNizszN M3vXdHNCVkeHUh?=
CTB-1 NEGzW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu1NmZKSzVyPUeuO|YyPzVizszN MYrTRW5ITVJ?
5637 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\ZbVFKSzVyPUeuPVI5PiEQvF2= NGnmPWJUSU6JRWK=
U251 NEPXUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nxNGlEPTB;Nz65OFAyPiEQvF2= NWnWdVdUW0GQR1XS
HOS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXLTYJKSzVyPUiuNlMxODdizszN NYSwcIdFW0GQR1XS
DOHH-2 M3fWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zld2lEPTB;OD6yN|U5KM7:TR?= NUHsSFFqW0GQR1XS
EW-1 NYnndoN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GzeGlEPTB;OD6zNFA5QCEQvF2= MmfKV2FPT0WU
BV-173 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnLTWM2OD16LkW1OVQh|ryP NH\lZ5NUSU6JRWK=
8-MG-BA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\SbWlEPTB;OD62PFk5QCEQvF2= NIPh[HJUSU6JRWK=
NB69 NU\BRWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTKc2RKSzVyPUiuO|A6OjFizszN NW\YeIQyW0GQR1XS
NCI-H69 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv1[VFKSzVyPUmuPVA6PjFizszN M2DReHNCVkeHUh?=
RS4-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLBd2JHUUN3ME2xNU4zOjB6IN88US=> M{jHWXNCVkeHUh?=
ONS-76 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3oTWM2OD1zMT6yPVQ4KM7:TR?= M37NTHNCVkeHUh?=
SF539 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\mdlJKSzVyPUGxMlQ5QDlizszN MYnTRW5ITVJ?
HuO-3N1 NHnpTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj1TWM2OD1zMT61O|k3KM7:TR?= MmTKV2FPT0WU
NCI-H1651 NVWzb45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn2eJBkUUN3ME2xNk4{OTF3IN88US=> NE\uc4FUSU6JRWK=
KARPAS-45 NXjBe3FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX1TWM2OD1zMj6zO|Yh|ryP MmrFV2FPT0WU
SK-NEP-1 NFjq[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXjTWM2OD1zMj60OlA6KM7:TR?= NVLTcppxW0GQR1XS
LAMA-84 NGKyXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rmO2lEPTB;MUOuNVA6PSEQvF2= NIX1VHBUSU6JRWK=
NCI-H1155 NHvmSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HpUGlEPTB;MUOuNlg2PiEQvF2= NHzUSllUSU6JRWK=
CTV-1 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF|LkS0OUDPxE1? Mlf4V2FPT0WU
QIMR-WIL NH[5enNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF|Lke4NVQh|ryP NHXle2JUSU6JRWK=
H9 M4TNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W1dmlEPTB;MUOuPFQ4PSEQvF2= NWDESIF[W0GQR1XS
SK-MEL-1 MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f5OGlEPTB;MUOuPVM1PyEQvF2= NWXybGlqW0GQR1XS
HD-MY-Z NEPVToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17JVWlEPTB;MUSuNFY{PyEQvF2= NFj4UopUSU6JRWK=
TI-73 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn0bmRIUUN3ME2xOE4zOzV4IN88US=> NGjpOHNUSU6JRWK=
JVM-3 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rZVWlEPTB;MUWuOVcyPiEQvF2= NYPyN3BvW0GQR1XS
D-247MG NYLi[YtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;jbmlEPTB;MUWuOVk{KM7:TR?= MWjTRW5ITVJ?
VA-ES-BJ NX7WWFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPI[o9KSzVyPUG1MlYxQTdizszN NV:yS4pNW0GQR1XS
NOS-1 Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Px[2lEPTB;MUWuOlUzOiEQvF2= NG\OUIxUSU6JRWK=
MOLT-4 NInpR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzJTWM2OD1zNj63OVIh|ryP NG[1UZBUSU6JRWK=
Mo-T NU\ObGpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\YcmJKSzVyPUG3MlA5PDlizszN MVXTRW5ITVJ?
NCI-H1770 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5LkG1OFMh|ryP MkfBV2FPT0WU
COLO-320-HSR M{fMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zORmlEPTB;MUeuNVgzPyEQvF2= MWfTRW5ITVJ?
TE-12 NGXSSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfmNXJKSzVyPUG3MlcxPTRizszN Ml;nV2FPT0WU
NCI-H82 MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u0T2lEPTB;MUeuPFczQCEQvF2= MVzTRW5ITVJ?
NEC8 NVT3XJhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofJTWM2OD1zOD6xN|E3KM7:TR?= MmO1V2FPT0WU
HSC-3 NYrLSYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjQ[mhyUUN3ME2xPE44PDF2IN88US=> MoGwV2FPT0WU
NCI-H1092 NGDHe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LpZmlEPTB;MUiuO|U6PSEQvF2= M2DjeHNCVkeHUh?=
NCI-H292 NGfETmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXFTWM2OD1zOT6wOFg6KM7:TR?= MVPTRW5ITVJ?
L-428 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\kT2lEPTB;MUmuOVU6KM7:TR?= M2q5[XNCVkeHUh?=
LU-134-A NIHJ[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHxSXN1UUN3ME2xPU42PzJizszN MX\TRW5ITVJ?
GI-ME-N MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:xTWM2OD1zOT61O|Q4KM7:TR?= MYfTRW5ITVJ?
ALL-PO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlTXRJUUN3ME2xPU42QTd{IN88US=> M2W0bXNCVkeHUh?=
D-283MED MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO2cXJtUUN3ME2xPU46OTVizszN M3vMRnNCVkeHUh?=
D-423MG NYWwbnJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\QXmVKSzVyPUG5Mlk6PjdizszN MnfSV2FPT0WU
CAKI-1 M3q3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jhXGlEPTB;MkCuNlIyQSEQvF2= MVXTRW5ITVJ?
ETK-1 NIrPNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi1XHNCUUN3ME2yNE4zPjF3IN88US=> NHPieHFUSU6JRWK=
G-402 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLT[2NGUUN3ME2yNE42OzN2IN88US=> NF:0OXhUSU6JRWK=
HL-60 M1jadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULhdJlmUUN3ME2yNU4yPjF|IN88US=> M3zOd3NCVkeHUh?=
A2058 NGGxVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mZZdKSzVyPUKxMlQ1PzdizszN NXXCfZhmW0GQR1XS
CHP-212 M37ETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKzT4xKSzVyPUKxMlkxPTFizszN MorWV2FPT0WU
KY821 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XsPWlEPTB;MkGuPVc2KM7:TR?= M2G2U3NCVkeHUh?=
TYK-nu NVrrW5JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XuNmlEPTB;MkKuNFY2OSEQvF2= NVraPG95W0GQR1XS
JVM-2 NIi5WZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPvVXFKSzVyPUKyMlI6QDNizszN NGi1e3VUSU6JRWK=
KU812 NFXOTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSwZVBKSzVyPUKyMlc{OTJizszN MY\TRW5ITVJ?
MKN28 M1fwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\CVWlEPTB;MkKuPVAyPSEQvF2= MkTxV2FPT0WU
ECC10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKzdVNKSzVyPUKzMlc1OSEQvF2= NULDUXh7W0GQR1XS
BHT-101 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3bmlEPTB;MkSuNFAxQCEQvF2= MmrPV2FPT0WU
DU-4475 M4HGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HKTGlEPTB;MkSuN|M{PyEQvF2= MXvTRW5ITVJ?
769-P NWHXNYVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ2Lki0OlYh|ryP NYHKS4s1W0GQR1XS
HEC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnzWmtKSzVyPUK1MlQ1PSEQvF2= M4SxWHNCVkeHUh?=
MOLT-13 NH\OfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GOZlKSzVyPUK1MlU{OzFizszN Mki3V2FPT0WU
8505C MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV34d2NuUUN3ME2yOk41QTd5IN88US=> NUfyR|FwW0GQR1XS
GB-1 NV3SNW5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vOeWlEPTB;Mk[uO|E4PiEQvF2= MmnxV2FPT0WU
SF126 M3\2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlniTWM2OD1{Nj63OlQ5KM7:TR?= M1\ubnNCVkeHUh?=
A4-Fuk MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ5LkGyO|Eh|ryP NV3XW3ZKW0GQR1XS
OVCAR-8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDnTWM2OD1{Nz6xOVM6KM7:TR?= MX7TRW5ITVJ?
NCI-H1304 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPHW|hFUUN3ME2yO{42PCEQvF2= MofLV2FPT0WU
GR-ST NXPhTnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXGVVBqUUN3ME2yPE4xPDdizszN MnPRV2FPT0WU
G-401 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m5NWlEPTB;MkiuOVA6PiEQvF2= NVfYVnZKW0GQR1XS
LXF-289 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ6LkW2OVEh|ryP M{TwfnNCVkeHUh?=
DBTRG-05MG M3\VUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ6LkmyNFQh|ryP MWjTRW5ITVJ?
YKG-1 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm0OHVKSzVyPUK5Mlg3QCEQvF2= Mn7KV2FPT0WU
GAMG MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ7Lkm5N{DPxE1? NYnuflJiW0GQR1XS
HCT-116 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z0b2lEPTB;M{CuNFU1QCEQvF2= MoGzV2FPT0WU
S-117 MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YR5UxUUN3ME2zNU4zOjV5IN88US=> NGnXcZpUSU6JRWK=
NCI-H1693 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX4TWM2OD1|Mz62OVQzKM7:TR?= MlPSV2FPT0WU
A427 NUDic45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7JdpY{UUN3ME2zN{46QTd4IN88US=> NV3FZop4W0GQR1XS
HT-29 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlviTWM2OD1|ND62NFMzKM7:TR?= NH;BZWRUSU6JRWK=
P12-ICHIKAWA NGjoU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN2Lke0PVEh|ryP MofsV2FPT0WU
CAL-51 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHFTWM2OD1|NT6wO|A6KM7:TR?= M4nrWHNCVkeHUh?=
Ramos-2G6-4C10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXQWHhIUUN3ME2zOU4zPDJ3IN88US=> Moj2V2FPT0WU
SCH NHv3dldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGn6U2dKSzVyPUO2MlQyPzRizszN Mlv2V2FPT0WU
SK-MEL-24 M2TUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLxc216UUN3ME2zOk46ODR2IN88US=> MmfEV2FPT0WU
SW1573 NILhcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\LSG9OUUN3ME2zPE44OjF4IN88US=> Mnv1V2FPT0WU
BALL-1 NXTHfVJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3CTWM2OD1|OT6yNVI6KM7:TR?= NXW4PZpCW0GQR1XS
BE-13 NYPKdZF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvNeWlKSzVyPUO5MlMzQSEQvF2= MkXMV2FPT0WU
GI-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTN7Lki2OFch|ryP MWLTRW5ITVJ?
GOTO NXPlPHBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnxZ5pWUUN3ME2zPU46OTN7IN88US=> MlzXV2FPT0WU
A673 NIn1cZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnETWM2OD12MT6wN|Q{KM7:TR?= M4[w[nNCVkeHUh?=
KG-1 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr2cIVYUUN3ME20N{4{QTRizszN NHzI[YpUSU6JRWK=
GP5d M4DJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XsTGlEPTB;NESuNFY3PiEQvF2= NIT4TYhUSU6JRWK=
MFM-223 NETneoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DRcGlEPTB;NESuNVIzQCEQvF2= NYfyfIpHW0GQR1XS
OAW-42 NWrKNlZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfwTWM2OD12ND6yOlQ{KM7:TR?= M4rvVnNCVkeHUh?=
C8166 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vRT2lEPTB;NEWuNFgzOiEQvF2= NIexN5BUSU6JRWK=
LU-99A MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTR4LkGzNlIh|ryP M{XvT3NCVkeHUh?=
NCI-H23 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7pTWM2OD12Nj6xO|g2KM7:TR?= Mlj4V2FPT0WU
HO-1-N-1 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS3W3FKSzVyPUS3MlA6QThizszN NGHNWpBUSU6JRWK=
A3-KAW NE\vUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDlTWM2OD12Nz6xNFA4KM7:TR?= NXjFVWN3W0GQR1XS
CGTH-W-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR5LkWwOlkh|ryP MkXyV2FPT0WU
DJM-1 M4DMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G5RmlEPTB;NEeuOVQyOyEQvF2= MkD1V2FPT0WU
A101D NGTq[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK3fFgzUUN3ME20O{43OzV5IN88US=> NVHVfFVsW0GQR1XS
BB30-HNC NXG1NIxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR6LkOwO|Ih|ryP MUjTRW5ITVJ?
T98G NXfFOm1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX4fWRKSzVyPUS4MlQ3OzNizszN NX\uTXJCW0GQR1XS
NCI-H1573 M1\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW1WGNxUUN3ME20PU41PDZ{IN88US=> NXv2PJdlW0GQR1XS
MEG-01 NX\CN3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTR7Lke0NVEh|ryP M2Dod3NCVkeHUh?=
WM-115 M2XLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HNS2lEPTB;NEmuPVIzOiEQvF2= MoSzV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID